Akron Molecules AG Report issue

For profit Phase 2 Phase 4
Founded: Vienna Austria (2010)
Status: No NME R&D (2010)

Organization Overview

First Clinical Trial
2013
NCT02003118
First Marketed Drug
None
First NDA Approval
None
Last Known Activity
2015

Timeline

NOW
  • Now

Alternative names

Akron Molecules

Active Ingredients

Drugs in Phase 4 Trials (3)

fentanyl (Innovar) (1 trial)

midazolam (versed) (1 trial)

sodium chloride (1 trial)

Drugs in Phase 2 Trials (1)

akr 202 (1 trial)

Indications

Experimental Indications (Clinical Trials, Phases 1-4)


 

Osteoarthritis (Phase 2)

Overview

  • Highest Phase: Phase 4
  • # of Trials: 2
  • # of Trial APIs: 4